Ascendis Pharma A/S (ASND) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $16.90B and a free-cash-flow yield of 0.3%. Over the most recent reported fiscal year, revenue grew 98.0%. Nama's AI scorecard rates it Buy, 6.5 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Buy · 6.5/10
Positive, at the low end of Buy. As of Nov 7, 2026.
Momentum
Middle · +14.6% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-9.0%
How far the last close sits under the highest price of the past five years.
Market cap
$16.90B
Trailing P/E
—
Price / book
10.5
Price / sales
14.4
FCF yield
0.3%
Dividend yield
—
Gross margin
91.3%
Operating margin
25.1%
Net margin
70.8%
Revenue growth (YoY)
+98.0%
Revenue growth (3-yr annual)
+141.4%
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
—
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
ASND earnings
Beat the EPS estimate in 2 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 13, 2026
$0.90
$0.77
+16.9%
$380.28M
Q1 2026
May 7, 2026
$0.27
-$0.08
+437.5%
$276.40M
Q4 2025
Feb 11, 2026
-$0.55
-$0.24
-129.2%
$277.40M
Q3 2025
Nov 12, 2025
-$1.00
-$0.12
-733.3%
$239.45M
ASND analyst price target
Median target $302.51 from 21 analysts, ranging $260.61 – $341.70.
Nama's AI scorecard currently rates Ascendis Pharma A/S Buy (6.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is the ASND price target?
The median analyst price target from 21 analysts is $302.51, with a range of $260.61 – $341.70.
Is ASND Shariah compliant?
Nama's AAOIFI-style screen reads Ascendis Pharma A/S as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.